

- Enterococci. *See also* Enterococcal infections
antimicrobial resistance in, 150e-9, 941t, 976
characteristics of, 971-972
genome of, 776, 972-973
laboratory identification of, 971-972, 972f
virulence factors of, 972
- Enterococcus faecalis*, 941t, 972, 976. *See also*
Enterococcal infections
- Enterococcus faecium*, 941t, 972, 976. *See also*
Enterococcal infections
- Enterocolic fistula, 268
- Enterocolitis
necrotizing, 991
neutropenic, 488, 1099, 1797-1798, 1798f
radiation, 270
sexually acquired, 881
- Enterocytozoon bienersi*, 1257
- Enteroglucagon, pNET secretion of, 559t, 571
- Enterohemorrhagic *E. coli* (EHEC). *See also*
Escherichia coli infections, intestinal
characteristics of, 852, 1028t, 1030
epidemiology of, 1028t, 1030
food-borne, 856t, 857
global considerations in, 1030
- Enteroinvasive *E. coli* (EIEC), 1028t, 1031.
See also Escherichia coli infections,
intestinal
- Enterokinase, 2090
- Enterokinase deficiency, 1937
- Enteropathic arthritis, **2178**
clinical features of, 2178-2179
diagnosis of, 2179
epidemiology of, 2178
historic background of, 2178
pathology of, 2178
treatment of, 2179
- Enteropathogenic *E. coli* (EPEC), 852, 1028t,
1030-1031. *See also Escherichia coli*
infections, intestinal
- Enteropathy
gluten-induced. *See* Celiac disease (gluten-
induced enteropathy)
HIV, 1257
protein-losing, **1945**
- Enteropathy-type T-cell lymphoma, 135e-3, 708
- Enteroscopy, 346e-1v, 1881, 1883f
- Enterotoxigenic *E. coli* (ETEC). *See also*
Escherichia coli infections, intestinal
adherence of, 852
characteristics of, 1028t, 1030
epidemiology of, 1028t, 1030
food-borne, 856t
toxin production in, 853
- Enterotype analysis, 86e-5-6
- Enterovirus(es), 1289-1290. *See also*
Coxsackievirus
- Enterovirus infections, **1290**. *See also*
Coxsackievirus infections
acute hemorrhagic conjunctivitis, 1293, 1293f
clinical syndromes associated with, 1291t,
1293
diagnosis of, 1293
encephalitis, 1291
epidemiology of, 1290, 1293
exanthems, 1292, 1292f
generalized disease of the newborn, 1291
global considerations in, 1290, 1292
hand-foot-and-mouth disease. *See* Hand-foot-
and-mouth disease
herpangina, 1293
immunity to, 1290
meningitis, 892, 1291
myelitis, 2657
neurologic complications of, 1293
nonspecific febrile illness (summer grippé),
1291
pathogenesis of, 1290
pleurodynia, 1291
poliovirus. *See* Poliovirus infection
rash in, 127, 133t, 1292
treatment of, 1293-1294
upper respiratory, 226, 1202t, 1293
- Enthesitis, 2219t
- Entomologic inoculation rate, 1371
- Entrance block, 273e-3
- Entrapment neuropathy, 49, 463e-4
- Entropion, 199, 1172
- Entry inhibitors. *See* Combination antiretroviral
therapy (cART)
- Enuresis, sleep, 192
- Envelope protein, HIV, 1216, 1219
- env* gene, 225e-1, 225e-2, 225e-3f, 1219, 1219f
- Environmental tobacco smoke. *See* Smoking,
passive exposure to
- Enzalutamide, 103e-15, 586
- Enzyme(s). *See specific enzymes*
- Enzyme immunoassay (EIA), 150e-2, 1245
- Enzyme-linked immunosorbent assay (ELISA),
214e-8
- Eosinopenia, 423
- Eosinophil(s), **422**
in adaptive immunity, 372e-7t
in asthma, 1673
disorders of, 422-423
functions of, 422
hematopoietic differentiation of, 89e-3f
in inflammation, 372e-8-9
in innate immunity, 372e-7t, 372e-8, 372e-14f
morphology of, 416f
in parasitic infections, 245e-4, 245e-6t, 422
in peripheral blood smear, 81e-6f
- Eosinophil chemotactic factor of anaphylaxis
(ECF-A), 372e-15t, 422
- Eosinophil granules, 422
- Eosinophilia. *See also* Hypereosinophilic
syndromes (HES)
clonal, 135e-7
diseases associated with, 422
drug-induced, 422
FGFR1-mutated, 135e-8
infectious causes of, 764, 765t
paraneoplastic, 612t, 613
parasites associated with, 245e-4, 245e-6t, 255e-1
PDGFR-mutated, 135e-8
primary, 135e-7, 135e-7t
tropical pulmonary, 422
- Eosinophilia-myalgia syndrome (EMS)
clinical features of, 376, 423, 2155, 2195
pathophysiology of, 423
L-tryptophan ingestion and, 14e-3, 376, 423,
462e-20, 2155
- Eosinophilic esophagitis, **1908**
clinical features of, 1909
diagnosis of, 1895, 1897f, 1909, 1909f
dysphagia in, 257, 1895
epidemiology of, 1908
etiology of, 1908
GERD and, 1908
histopathology of, 1909, 1909f
treatment of, 257, 1909
- Eosinophilic fasciitis, 376, 664, 2165
- Eosinophilic gastritis, 1931-1932
- Eosinophilic gastroenteritis, 270, 1939, 1940t
- Eosinophilic granulomatosis with polyangiitis
(Churg-Strauss syndrome), **2186**
ANCA in, 1685, 2180
clinical features of, 1685, 1840, 2186
diagnosis of, 386e-1, 386e-3f, 1685, 1840,
2186-2187
incidence and prevalence of, 2186
pathology and pathogenesis of, 2180, 2186
pericardial effusion in, 386e-3f
prognosis of, 1686
renal involvement in, 1840
treatment of, 1685-1686, 2187
- Eosinophilic leukemia, chronic, 135e-7-8,
135e-7t, 422, 672
- Eosinophilic myocarditis, 1562
- Eosinophilic myofasciitis, 2198
- Eosinophilic pneumonia. *See* Pulmonary
infiltrates with eosinophilia
- Eosinophilic pustular folliculitis, 1263
- Eotaxin (CCL11), 372e-12t, 1674, 1674f
- EPB41* gene mutations, 653t
- EPB42* gene mutations, 653t
- EPEC (enteropathogenic *E. coli*), 852, 1028t,
1030-1031. *See also Escherichia coli*
infections, intestinal
- Ependymomas, 441e-39f, 601
- Ephedra sinica* (ma huang), 14e-3, 2547t
- Ephedrine, 305, 473e-8t
- Ephelides, 359, 360t
- Ephrins, 102e-15, 102e-15f
- Epicondylitis, 2219t, 2249
- Epidemic polyarthritis (Ross River virus
infection), 837, 1313
- Epidemic (louse-borne) typhus
clinical features of, 128t, 782, 1155t, 1158
diagnosis of, 1158
epidemiology of, 127, 128t, 782, 1155t, 1158
global considerations in, 1158
prevention of, 1158
skin manifestations of, 128t
treatment of, 1158
- Epidemiologic transition, **266e-1**, 266e-1t
in United States, 266e-1-2
worldwide variations in, 93e-5, 93e-5f, 93e-5t,
266e-2
- Epidermal growth factor (EGF), 400e-1t, 1912,
1913f, 2285
- Epidermal growth factor receptor (EGFR), 39t,
41, 103e-16, 507, 1932. *See also EGFR*
gene mutations
- Epidermal growth factor receptor (EGFR)
antibodies, 103e-21, 103e-21t
- Epidermal growth factor receptor (EGFR)
inhibitors
action of, 103e-16, 103e-17t
adverse effects of, 103e-26, 356, 356t,
378-379
for head and neck cancer, 505
for lung cancer, 103e-16, 103e-17t, 507, 521,
521t
resistance to, 103e-23
- Epidermoid cysts, 76e-4f, 364, 603
- Epidermolysis bullosa, 257, 434, 2513
- Epidermolysis bullosa acquisita, 361t, 362, 370t,
373
- Epididymitis, 870t, 871-872, 1168, 1170t
- Epididymoorchitis, 194e-3, 231e-2
- Epidural abscess
anaerobic bacterial, 1098
clinical features of, 784
cranial, 904-905, 904f
etiology of, 780t
intracranial, 784
spinal, 117, 780t, 784, 2654, 2655f
treatment of, 767t, 780t, 2655
- Epidural anesthesia, 54
- Epidural hematoma, 441e-32f, 457e-3, 457e-3f,
2655
- Epidural metastases, 606, 606f, 1790
- Epidural spinal cord compression, 2653, 2653f
- Epidural spinal hemorrhage, 2584
- Epigenetic events
in cancer cells, 102e-7-8, 102e-8f
gene expression and, 101e-4, 429-430, 431f
- Epigenetic marks, 455
- Epigenetics, 102e-7, 444e-1-2
- Epigenome, 429
- Epigenomics, 6
- Epiglottitis, **234**, 235f, 1011, 1207
- Epilepsy, 334
- Epilepsia partialis continua, 616, 2542
- Epilepsy, **2542**. *See also* Seizure(s)
autonomic, 147
catamenial, 2559
coma in, 1773
continuous seizures in. *See* Status epilepticus
definition of, 2542
EEG in, 442e-1-2, 442e-2f
employment and, 2558-2559
etiology of, 2544-2545
age-related, 2545-2547, 2546t
channelopathies, 444e-2, 444e-2t
drug-related, 2547t
genetic factors, 444e-2t, 2545t, 2548
incidence of, 2542
interictal behavior in, 2557-2558
loss of driving privileges in, 2559
magnetoencephalography in, 442e-3
mortality data, 2558